Q4 2025 · 13F-HR
Foresite Capital Management IV, LLCholdings as filed
Filed 2026-02-17 · accession 0001104659-26-015407
$229.7M
Reported value
7
Positions
2025-12-31
Period end
The Brief · Foresite Capital Management IV, LLC · Q4 2025
AI · grounded in 13F
Foresite Capital Management IV, LLC established a new position in Alector, Inc. ALEC valued at $6.06M. The fund added one position and reduced none during the period. Total assets under management reached $229.71M across seven positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N69605108 | PHVS | Pharvaris N.V. | $132.6M | 57.7% | 4,778,581 | Common | SOLE |
| 23282W605 | CYTK | CYTOKINETICS INC | $29.1M | 12.7% | 458,295 | Common | SOLE |
| 55083R203 | LYEL | Lyell Immunopharma, Inc. | $24.6M | 10.7% | 800,399 | Common | SOLE |
| 578784100 | MAZE | Maze Therapeutics, Inc. | $21.7M | 9.43% | 522,657 | Common | SOLE |
| 75943R102 | RLAY | Relay Therapeutics, Inc. | $8.5M | 3.68% | 1,000,000 | Common | SOLE |
| 98420N105 | XENE | Xenon Pharmaceuticals Inc. | $7.2M | 3.12% | 160,000 | Common | SOLE |
| 014442107 | ALEC | Alector, Inc. | $6.1M | 2.64% | 3,887,200 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.